# A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

> **NCT00373256** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 488 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** paclitaxel
- **DRUG:** bevacizumab
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00373256
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-06
- **Final completion:** 2011-08
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2012-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00373256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00373256, "A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00373256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*